Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

Washington State wants to bring a Netflix model to Hepatitis C care on an RFP model winner-take-all basis. If cost is the major factor here, Gilead could win this contract. By itself, it wouldn't ...

Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the separation of the Chairman and CEO roles and developing a ...

Gilead agreed to provide lenacapavir at cost for two-to-three years while six generic drugmakers, which were granted licenses to make the medicine for low-income countries, ramp up production.

Besides Ascent-04, Gilead expects a readout by June from the phase 3 Ascent-03 trial pitting Trodelvy against chemo in first-line, PD-L1-negative metastatic TNBC.

In a statement, Gilead said it had sought the orphan status to expedite approval of the drug, in particular a required pediatric study plan that, without such a designation, the company said could ...

A doctor holds Truvada pills at her office in San Francisco in 2012. An HIV-prevention group alleges that Gilead postponed development on a safer drug so it could continue to gain monopoly profits ...

The dominoes keep falling at Gilead Sciences. ... the Big Biotech has paused enrollment of magrolimab solid tumor trials following the FDA's request for a partial clinical hold on the anti-CD47 ...

In March 2019, at PrEP4All’s request, one of us (CM) analyzed the CDC’s patents and concluded that the patents appear valid, enforceable, and infringed by Gilead.

The lawsuit stems from a 2005 agreement between Gilead, Royalty Pharma and Emory University around emtricitabine, which is an important part of Gilead's multibillion-dollar HIV franchise.

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.